Krista Rossi of MD Magazine reports on a presentation at the American Heart Association (AHA) Scientific Sessions 2018, in Chicago, IL. A team of clinical investigators presented on the cost-effectiveness of PCSK9 inhibitor alirocumab. They found that the drug was cost-effective at a price of $6,319 annually per the $100,000 willingness to pay threshold in the overall population as reported by Ms. Rossi. Follow the link to read Ms. Rossi’s article for more details. For more on PCSK9 see the here.